Artificial Intelligence in Medical Imaging Market Size & Share 2026-2035

Artificial Intelligence in Medical Imaging Market Size

The global artificial intelligence in medical imaging market reached USD 2.1 billion in 2025. The market is projected to advance from USD 2.8 billion in 2026 to USD 19.6 billion by 2035, compounding at a CAGR of 23.9% over the forecast period, according to the latest report published by Global Market Insights Inc.

The convergence of deep learning technologies with clinical imaging workflows is fundamentally redefining diagnostic precision, with AI algorithms now demonstrating area under the curve values comparable to experienced radiologists across multiple modalities. The scale of adoption is validated by the cumulative authorization of over 1,500 AI-enabled medical devices by the U.S. Food and Drug Administration as of mid-2026, with radiology accounting for approximately 76% of all authorizations.^{[1]U.S. Food and Drug Administration, fda.gov} The World Health Organization's resolution WHA78.13, adopted in May 2025, further institutionalizes this trajectory by explicitly endorsing AI integration into radiology information systems as a strategic pathway to equitable global access to diagnostic imaging.

Key Drivers

Drivers Impact Analysis

Technological Advancements in AI

Advancements in deep learning, transformer-based architectures, and computer vision are expanding AI capabilities across imaging analysis, workflow automation, and clinical applications. Modern convolutional neural networks have demonstrated liver segmentation accuracy with Dice scores routinely exceeding 95% in controlled clinical studies, and peer-reviewed meta-analyses report AUC values of 0.864 to 0.937 for AI-driven lung nodule detection on chest radiographs and CT scans. The rapid increase in FDA-cleared radiology AI tools 295 devices authorized in 2025 alone with radiology securing 75% of all AI/ML clearances reflects the depth and reliability of underlying technology advancements. These gains are accelerating vendor product pipelines and expanding clinical deployment beyond academic settings into community hospitals and outpatient imaging centers.

Shortage of Radiologists Accelerating AI Adoption

A growing structural imbalance between imaging demand and available radiologist supply is intensifying dependence on AI-assisted workflows. The Harvey L. Neiman Health Policy Institute projects that imaging utilization will increase 16.9% to 26.9% by 2055, driven by rapid growth in older age groups, while radiologist supply is projected to grow only 25.7% over the same period under current residency conditions. The Association of American Medical Colleges estimated a 4.3% general physician shortage in 2024, with radiology among the affected specialties.^{[2]Harvey L. Neiman Health Policy Institute, neimanhpi.org} AI triage tools and automated reporting solutions are being adopted as a structural response, enabling radiologists to concentrate on complex case interpretation rather than routine throughput.

Improved Diagnostic Accuracy and Treatment Planning

AI-driven imaging enhances early disease detection, reduces inter-reader diagnostic variability, and improves precision in treatment planning across oncology, cardiology, and neurology. A systematic review and meta-analysis published in a peer-reviewed journal found that deep learning algorithms achieved AUC values of 0.868 to 0.909 for breast cancer detection across mammography, ultrasound, MRI, and digital breast tomosynthesis, approaching or matching the performance of specialist radiologists. Regulatory-grade evidence supporting diagnostic accuracy is accelerating hospital procurement cycles and expanding reimbursement coverage in key markets.

Rising R&D Investment Supporting Innovation and Market Expansion

Increasing investments by healthcare IT companies, imaging vendors, academic medical centers, and early-stage startups are accelerating product development cycles and broadening the clinical application scope of AI imaging. National Institutes of Health funding directed through the National Institute of Biomedical Imaging and Bioengineering continues to support foundational research in low-dose MRI reconstruction, AI-assisted cardiac imaging, and multi-modal data integration. Enterprise AI imaging platforms are attracting substantial private capital, particularly for applications in oncology and cardiovascular imaging where reimbursement pathways are maturing.

Key Challenges

Restraints Impact Analysis

Slow Regulatory Approval Process

Stringent and evolving regulatory requirements for AI-based medical devices can delay product commercialization and increase time to artificial intelligence in medical imaging market, particularly as dual compliance obligations expand. In the European Union, manufacturers must now navigate both the Medical Devices Regulation (EU MDR 2017/745) and the EU AI Act (Regulation EU 2024/1689), with the Medical Device Coordination Group publishing comprehensive interplay guidance (MDCG 2025-6) in June 2025 to clarify overlapping conformity assessment obligations. In the United States, the FDA's median clearance time for AI/ML medical devices stood at 142 days in 2025, representing a meaningful commercialization lag for vendors with large product pipelines. These regulatory timelines affect smaller developers disproportionately, constraining competitive entry and increasing time to first revenue.

Risk of Patient Safety Concerns Due to AI-Driven Diagnostic Errors

Potential inaccuracies, algorithmic biases, or distribution shifts between training and deployment populations may impact clinical decisions and limit physician confidence in AI recommendations. Research indicates that deep learning algorithms trained on curated academic datasets can underperform when deployed in community or resource-constrained settings where image acquisition protocols and patient demographics diverge from training conditions. This generalizability gap remains one of the most consequential barriers to broad clinical adoption, particularly in high-stakes specialties such as neurology and oncology where diagnostic errors carry significant patient safety consequences. Regulatory frameworks are increasingly requiring real-world performance monitoring, adding post-market surveillance obligations that raise operational costs for AI vendors.
 

Artificial Intelligence in Medical Imaging Market Trends

Expansion of Enterprise AI Imaging Platforms

The most consequential structural shift underway in the AI medical imaging market is the migration from point-solution AI tools toward integrated enterprise platforms that consolidate detection, workflow management, and diagnostic reporting across all modality types within a single infrastructure layer. Historically, AI deployments were fragmented across individual clinical use cases a separate tool for chest nodule detection, another for brain lesion segmentation, a third for fracture identification creating integration overhead that limited scalability in health system deployments. The more consequential shift is the emergence of vendor-agnostic orchestration layers that sit above the PACS environment and route imaging studies through multiple AI algorithms in parallel, delivering consolidated outputs directly into radiology reporting workflows.

GE HealthCare's Edison platform and Siemens Healthineers' AI-Rad Companion represent commercial-scale deployments of this architecture, enabling hospitals to deploy and manage large AI algorithm libraries across enterprise-wide imaging networks. The underlying driver is the operational complexity of managing individually licensed AI tools at scale, which is creating strong purchasing preference for consolidated platform approaches that reduce IT overhead and simplify regulatory compliance documentation. In our Q2 2025 primary research covering 280 radiology department heads across 12 countries, 71% reported that enterprise platform integration capability was the primary vendor selection criterion, superseding per-algorithm performance benchmarks for the first time. The data indicates a structural demand reorientation from algorithm-level evaluation to platform-level procurement, a shift that favors established imaging vendors with mature integration architectures and disadvantages standalone algorithm developers without platform partnership strategies.

Rising Adoption of Workflow Automation and Triage AI

Workflow automation and AI-assisted case triage represent the highest-adoption functional category within the AI medical imaging segment, driven by the direct, measurable impact on radiologist throughput and department operational efficiency. AI triage systems, which prioritize worklists by identifying critical findings such as intracranial hemorrhage, large vessel occlusion, and aortic dissection, have achieved the most extensive clinical validation and the largest number of regulatory clearances globally. The Lancet Oncology Commission, in its projections published through 2025, estimates a global diagnostic specialist shortfall of approximately 16 million by 2050, with radiologists and radiologic technologists comprising a significant portion of the gap, framing AI triage not as an efficiency tool but as a structural workforce solution.

A study published in Nature Communications in 2025 demonstrated that AI assistance on chest radiograph interpretation reduced clinician report interpretation time by 18.3% in real-world deployment involving 296 patients, while simultaneously improving structured report quality scores compared with standard practice. Viz.ai's platform, which delivers AI-detected critical findings directly to the on-call physician's mobile device, is deployed across more than 1,000 hospital sites globally, representing one of the most extensive real-world validations of AI triage impact at scale. The second-order effect of workflow automation extends beyond radiology into upstream clinical departments, as faster imaging turnaround reduces emergency department boarding times and compresses overall inpatient length of stay. At the segment level, triage AI adoption is advancing most rapidly in emergency radiology and acute stroke care pathways, where time-to-treatment metrics are directly tied to patient outcome and regulatory accountability.

Growing Integration of Multimodal Data and Advanced Analytics

• AI solutions are progressively expanding beyond single-modality image analysis toward integrated platforms that fuse imaging data with clinical records, laboratory results, genomic profiles, and longitudinal patient history to deliver comprehensive diagnostic and prognostic outputs. This multimodal integration trajectory reflects a fundamental reconceptualization of medical imaging AI from a pattern-recognition tool to a clinical decision support system embedded within the broader patient data ecosystem. The underlying driver is the growing body of evidence that multi-input AI models outperform image-only models in predicting clinical outcomes such as disease recurrence, treatment response, and early-stage disease identification.
• A review of deep learning approaches in medical image analysis published in PMC notes that federated learning and multi-modal data integration are among the most active areas of current research, with models trained on multi-site, multi-modality datasets demonstrating superior generalizability compared with single-institution image-only benchmarks. In practical deployment, Tempus Radiology is building radiology-genomics integration platforms that align imaging phenotypes with molecular biomarker profiles, creating clinical decision support outputs relevant to oncology treatment planning and trial patient selection. The commercial implications extend into precision diagnostics, chronic disease monitoring, and population health management, substantially expanding the total addressable market beyond traditional radiology workflow optimization. Of greater strategic consequence, multimodal AI platforms are creating proprietary dataset moats that advantage incumbents with access to large longitudinal imaging and clinical data archives, structurally reshaping the competitive basis of the segment over the medium term.

Artificial Intelligence in Medical Imaging Market Analysis

By Deployment

Cloud-Based

The cloud-based segment accounts for 57.6% of the global AI in medical imaging market in 2025 and represents the dominant deployment modality by a significant margin. Cloud infrastructure enables rapid algorithm deployment, seamless software updates, scalable compute capacity for large imaging datasets, and lower upfront capital expenditure for health systems, making it particularly attractive to mid-size hospitals and emerging market health networks that lack on-premises high-performance computing resources. The segment benefits directly from the enterprise platform trend, as cloud-hosted AI orchestration layers can be integrated with existing PACS and RIS systems through standard API connections without hardware procurement cycles. The regulatory environment has matured substantially in support of cloud deployment, with FDA clearance pathways now well-established for Software as a Medical Device (SaMD) products, further reducing commercialization friction for cloud-first vendors.

Major vendors including GE HealthCare through its Edison platform and Aidoc through its cloud-native AI operating system have built commercial-scale cloud deployment architectures validated across multi-site hospital networks in North America and Europe. Aidoc's ORB platform, which enables enterprise health systems to integrate and monitor AI algorithms from multiple vendors within a unified cloud-hosted framework, represents a commercial-scale example of cloud architecture driving both AI adoption and platform consolidation simultaneously. The growth trajectory of the cloud-based segment is further supported by the expansion of teleradiology services and outpatient imaging networks, where cloud-based AI enables AI-assisted interpretation without on-site radiologist presence or on-premises computing infrastructure.

On-Premises

The on-premises segment retains a 42.4% share of the AI in medical imaging market in 2025, reflecting persistent demand from institutions where data sovereignty, network latency, and regulatory compliance requirements preclude cloud deployment. Academic medical centers, government hospitals, and defense-related health facilities in regions with strict patient data localization regulations particularly in Germany, France, South Korea, and China represent the core on-premises demand base. On-premises deployments also remain preferred for real-time intraoperative imaging applications where network-dependent latency is clinically unacceptable.

The segment is evolving structurally, with vendors offering hybrid architectures that process time-sensitive inference workloads locally while offloading model training, software updates, and non-critical analytics to cloud environments, softening the historical binary between pure on-premises and pure cloud models. Siemens Healthineers and Philips Healthcare maintain strong on-premises installed base relationships through their existing imaging hardware platforms, providing a natural channel for on-premises AI software deployment. Canon Medical Systems' Advanced intelligent Clear-IQ Engine (AiCE), embedded within its Aquilion CT scanner line, exemplifies the on-premises approach of processing AI reconstruction algorithms natively at the scanner level, eliminating network dependency and maintaining full data localization compliance.

By Modality

X-Ray

X-ray represents the largest modality segment with a 27.1% share of the AI in medical imaging market in 2025, reflecting the combination of the highest global imaging volume, the most extensive dataset availability for model training, and the longest track record of AI regulatory clearances. AI applications in X-ray span chest radiograph interpretation, bone fracture detection, dental panoramic imaging, and tuberculosis screening in high-burden regions. The FDA's AI-enabled device list as of mid-2026 contains the largest concentration of radiology AI clearances in the chest X-ray category, with tools from Lunit, Aidoc, Annalise.ai, and Subtle Medical receiving authorization for clinical deployment.

The high specificity and sensitivity demonstrated by AI chest radiograph tools with AUC values reaching 0.93 in peer-reviewed meta-analyses has accelerated clinical confidence and hospital procurement in both high-income and emerging markets.^{[3]PubMed National Library of Medicine, pubmed.ncbi.nlm.nih.gov} X-ray AI is also the leading modality for AI deployment in resource-constrained settings, given the relatively lower cost of X-ray equipment and the availability of cloud-based inference for facilities without on-premises computing infrastructure. Qure.ai's qXR platform, deployed across government tuberculosis screening programs in more than 25 countries, demonstrates the scalability of X-ray AI across resource-limited health systems where the modality's accessibility creates the largest potential for AI-driven diagnostic impact.

Computed Tomography (CT)

Computed tomography accounts for 24.5% of the artificial intelligence in medical imaging market share in 2025 and represents the second-largest modality segment, driven by the complexity and volume of CT studies and the high clinical value of AI-assisted analysis across oncology, pulmonology, and cardiovascular applications. AI tools for CT lung nodule detection, liver segmentation, coronary artery calcium scoring, and stroke triage have achieved broad clinical validation and FDA clearance, with CT-based applications representing a disproportionate share of high-value radiology AI deployments in academic and tertiary care settings. Google's deep learning model for CT-based lung cancer screening demonstrated performance that outperformed radiologists following Lung-RADS protocols in controlled studies, establishing a benchmark for CT AI diagnostic capability.

Photon-counting detector CT, an emerging hardware platform now entering commercial deployment, is generating substantially richer imaging datasets that are expected to expand AI performance across multiple CT applications during the forecast period. Canon Medical Systems and Siemens Healthineers are both actively integrating AI reconstruction and analysis algorithms natively into their CT scanner platforms Canon through AiCE deep learning reconstruction and Siemens through its SOMATOM platform's embedded AI capabilities further embedding AI into the modality acquisition workflow. The structural demand for CT-based AI is reinforced by the expansion of national lung cancer screening programs in the United States and United Kingdom, which are generating higher CT scan volumes and strengthening the procedural throughput base that supports AI deployment economics.

Magnetic Resonance Imaging (MRI)

MRI accounts for 17.6% of the AI in medical imaging market in 2025 and represents one of the highest-growth modality segments within the forecast period, given the complexity of MRI interpretation, the long acquisition times that AI can compress, and the expanding clinical indications for MRI in neurology, oncology, and musculoskeletal imaging. AI applications in MRI include automated brain lesion segmentation, MRI reconstruction acceleration enabling scan time reductions of 50% to 75%, prostate cancer detection and grading, and cardiac function quantification. NIH funding through the National Institute of Biomedical Imaging and Bioengineering has supported multiple programs targeting low-dose and zero-dose contrast-enhanced MRI reconstruction using deep learning, reflecting the strategic priority placed on radiation-free MRI expansion.

Subtle Medical's SubtleMR platform, which uses deep learning to improve image quality and reduce acquisition time across 1.5T and 3T MRI systems, represents a commercially deployed example of AI driving both clinical performance improvements and operational throughput gains simultaneously. The segment is further supported by growing demand for fetal and pediatric MRI, where AI-assisted reconstruction and motion correction address longstanding technical challenges in these patient populations. At the clinical application level, prostate MRI analysis using AI for PI-RADS scoring and brain MRI analysis for multiple sclerosis lesion segmentation represent two of the highest-value emerging deployment categories within the modality, each attracting dedicated AI development investment from specialized vendors.

Ultrasound Imaging

Ultrasound imaging accounts for 12.3% of the AI in medical imaging market in 2025 and is experiencing accelerating AI adoption driven by the modality's portability, absence of radiation, and expanding clinical applications across obstetrics, cardiology, and point-of-care settings. AI applications in ultrasound include automated fetal biometry measurement, echocardiography analysis, thyroid nodule classification, and AI-guided acquisition assistance for less experienced operators, which is particularly impactful in settings where sonographer expertise is limited.

Butterfly Network's iQ+ handheld ultrasound system, paired with AI-assisted image optimization and clinical interpretation support, represents a commercial deployment that extends AI ultrasound capabilities to bedside, emergency, and resource-limited settings. The growing adoption of handheld ultrasound devices in primary care and telehealth workflows is creating a new AI deployment channel outside traditional radiology departments, expanding the total addressable market for ultrasound AI. AI-assisted cardiac ultrasound for automated ejection fraction measurement and wall motion analysis has received FDA clearance from multiple vendors, establishing reimbursement pathways that are supporting commercial uptake in cardiology practices. Samsung Medison is integrating AI acquisition guidance and automated measurement tools natively into its ultrasound platforms, reflecting the broader trend of hardware-embedded AI adoption across the modality.

Molecular Imaging

Molecular imaging accounts for 8.7% of the market in 2025 and encompasses PET, SPECT, and hybrid PET/CT and PET/MRI imaging, where AI is being applied to tracer quantification, lesion detection, and theranostics planning. The segment is characterized by smaller dataset sizes relative to CT or X-ray, reflecting the higher cost and procedural complexity of molecular imaging examinations, which historically constrained AI model training. OECD Health at a Glance 2025 data indicates that PET scanner availability is increasing across member countries as oncology treatment protocols expand, creating the procedural volume underpinning AI adoption in this segment.

AI applications in PET imaging for oncology staging, treatment response monitoring, and amyloid quantification in Alzheimer's disease are among the highest-value clinical use cases, attracting targeted AI development investment from specialized vendors. The integration of AI with theranostic dosimetry planning where AI models optimize radioligand therapy dosing based on PET-derived tumor dosimetry calculations represents an emerging high-value application segment within molecular imaging that is expected to gain commercial traction during the medium-term forecast period.

Nuclear Imaging

Nuclear imaging accounts for 6.5% of the AI in medical imaging market in 2025, representing a specialized but strategically important segment where AI is primarily applied to myocardial perfusion imaging analysis, bone scan interpretation, and thyroid scintigraphy. AI tools for automated myocardial perfusion SPECT analysis have achieved regulatory clearance and clinical deployment in multiple markets, enabling standardized quantification and reducing inter-reader variability in nuclear cardiology laboratories.

The segment faces structural volume constraints given the declining use of certain nuclear medicine procedures in favor of CT- and MRI-based alternatives in some clinical pathways, though theranostics growth is partially offsetting this trend. GE HealthCare's advanced nuclear medicine AI tools, integrated with its SPECT/CT platforms, represent the leading commercial example of AI-native nuclear imaging analysis at scale. Regulatory maturity for nuclear medicine AI applications is advancing in both the United States and European Union, supporting moderate growth within the segment during the forecast period, particularly for AI applications in nuclear cardiology and oncology theranostics where the clinical value proposition is most clearly defined.

Other Modalities

Other modalities collectively account for 3.3% of the market in 2025 and include emerging imaging applications such as optical coherence tomography (OCT), digital pathology whole-slide imaging, dermatoscopy, and capsule endoscopy, where AI algorithms are demonstrating strong diagnostic performance but commercial deployment remains early-stage. AI for retinal OCT analysis, developed by companies such as Google DeepMind and several ophthalmic device manufacturers, has generated AUC values of 0.933 to 1.00 across conditions including diabetic retinopathy, age-related macular degeneration, and glaucoma, representing some of the highest-performing diagnostic AI benchmarks in any modality. Regulatory frameworks for non-traditional imaging modalities are evolving, with the FDA and European regulators receiving an increasing number of submissions for AI tools operating on dermatoscopic and endoscopic image data. The long-term growth potential within this segment is substantial, as AI extends the reach of high-accuracy image-based diagnostics into primary care and community health settings where specialist access is limited.

By Indication

Lung Imaging

Lung imaging represents the largest indication segment with 22.8% of global market share in 2025, driven by the high prevalence of lung cancer, tuberculosis, and COVID-19 sequelae imaging demand, combined with the extensive body of AI validation evidence in pulmonary radiology. AI tools for lung nodule detection, lung cancer risk stratification, COVID-19 pneumonia quantification, and COPD severity assessment have collectively received more FDA clearances than any other indication category within radiology AI.

The clinical urgency of early lung cancer detection where five-year survival rates differ dramatically between early-stage and advanced diagnoses has created strong physician demand for AI tools that improve detection sensitivity on low-dose CT lung cancer screening examinations. Aidoc's lung AI suite and Lunit INSIGHT CXR, both commercially deployed at scale across multiple health systems, represent the leading product platforms in this indication. National lung cancer screening programs in the United States and United Kingdom are expanding eligibility criteria, generating higher CT scan volumes and strengthening the structural demand for AI-assisted lung imaging interpretation across both hospital and diagnostic center settings.

Breast Imaging

Breast imaging accounts for 18.1% of the AI in medical imaging market in 2025 and represents one of the most clinically mature AI indication segments, with multiple FDA-cleared and CE-marked AI tools commercially deployed in mammography screening programs globally. AI applications in breast imaging span mammography CAD (computer-aided detection), digital breast tomosynthesis (DBT) analysis, breast ultrasound lesion classification, and breast MRI lesion characterization.

A peer-reviewed meta-analysis reported AUC values of 0.868 to 0.909 for deep learning algorithms in breast cancer detection across multiple imaging modalities, supporting clinical confidence in AI-assisted mammography reading. Hologic's Genius AI Detection 2.0, which received FDA 510(k) clearance in 2025 under product code QDQ, is one of the most extensively deployed AI breast imaging tools in North American screening programs, demonstrating the commercial maturity of this indication segment. The European Society of Radiology has actively contributed to guidance frameworks for AI deployment in breast cancer screening, supporting regulatory standardization across EU member states and accelerating institutional adoption in national screening programs.

Cardiovascular Applications

Cardiovascular applications account for 17.6% of the market in 2025 and represent the fastest-growing indication within the forecast period, driven by the high disease burden of cardiac conditions globally, the complexity of cardiac image interpretation, and the expanding role of CT coronary angiography and cardiac MRI in clinical pathways. AI applications in cardiovascular imaging include automated ejection fraction measurement, coronary artery calcium scoring, CT-based fractional flow reserve (CT-FFR) analysis, aortic aneurysm sizing, and AI-assisted echocardiography interpretation.

Cleerly Inc.'s AI-driven coronary CT angiography analysis platform, which quantifies coronary artery plaque composition and stenosis severity, represents a commercial-scale deployment in the non-invasive cardiac imaging pathway, with clinical validation across large multi-center datasets. NIH funding through the National Institute of Biomedical Imaging and Bioengineering has supported research on AI-assisted coronary artery imaging using next-generation photon-counting detector CT, indicating the long-term technical trajectory for this indication. Cardiovascular AI reimbursement coverage in the United States and select European markets is maturing, reducing a historical barrier to clinical adoption and converting pilot deployments into full-scale procurement programs.

Orthopedics

Orthopedics accounts for 15.4% of the AI in medical imaging market in 2025 and is characterized by high procedural volume in fragmented musculoskeletal imaging, encompassing fracture detection, joint space analysis, implant positioning assessment, and osteoporosis screening. AI tools for fracture detection on X-ray particularly in the emergency department setting where missed fractures represent a significant clinical and medico-legal risk have achieved strong regulatory clearance traction and rapid commercial deployment.

RapidAI has expanded its acute care AI platform into musculoskeletal applications, and multiple specialized orthopedic AI vendors are active in bone age assessment and vertebral fracture grading on spinal imaging studies. The aging global population is driving procedural volume growth in orthopedic imaging, creating the throughput base that supports AI deployment economics in this indication. Automated bone density measurement and osteoporosis risk stratification from routine CT studies using AI to extract DEXA-equivalent measurements from imaging data acquired for other clinical purposes represents a high-potential emerging application within the orthopedics indication segment that could substantially expand AI utilization without requiring additional imaging procedures.

Neurology

Neurology accounts for 10.2% of the market in 2025 and encompasses AI applications in brain MRI, CT perfusion imaging for stroke triage, white matter lesion quantification, and neurodegenerative disease biomarker extraction. AI triage tools for acute ischemic stroke, detecting large vessel occlusion and core infarct volume on CT perfusion, have achieved some of the most compelling clinical outcome evidence in the AI imaging field, with multiple studies demonstrating reduced time to treatment and improved patient outcomes in settings where AI triage is active. RapidAI's RAPID platform and Viz.ai's LVO detection algorithm are the leading commercially deployed platforms in neurology AI triage, both with extensive FDA clearance portfolios and international deployment footprints spanning over 2,000 and 1,000 hospital sites respectively.

The Alzheimer's disease indication represents a growing development priority, with AI tools for amyloid PET quantification and hippocampal volumetry on MRI supporting clinical trial endpoint measurement and early diagnostic decision-making. Multiple sclerosis lesion segmentation and longitudinal tracking on brain MRI where AI can identify new or enlarging lesions with consistent inter-scan reliability is an additional high-value neurology application segment that is attracting targeted investment from both established imaging vendors and specialized AI developers.

Liver Imaging

Liver imaging accounts for 8.8% of the AI in medical imaging market in 2025 and focuses on AI applications in hepatocellular carcinoma detection, liver segmentation, non-alcoholic fatty liver disease (NAFLD) quantification, and cirrhosis staging. Deep learning liver segmentation models have demonstrated Dice scores routinely exceeding 95% in controlled studies, establishing a high technical performance baseline for AI liver analysis applications.

The rising global prevalence of NAFLD and metabolic-associated steatohepatitis (MASH), alongside the expanding use of MRI elastography and multiparametric liver MRI in clinical staging protocols, is creating new AI application opportunities in liver imaging. Philips Healthcare has developed AI-assisted liver MRI analysis tools integrated into its multi-parametric liver imaging protocols, representing a vendor-integrated approach to AI liver diagnostic support that leverages the company's hardware-software integration capability. The liver indication also benefits from growing demand for pre-operative surgical planning in hepatic surgery, where AI-generated 3D liver segmentation models from CT data are being used to support volumetric planning and reduce operative risk across complex hepatic and pancreatic surgical procedures.

Other Indications

Other indications collectively account for 7.1% of the market in 2025 and include AI applications in thyroid imaging, prostate cancer detection, renal imaging, gastrointestinal imaging, and ophthalmology, each of which is at varying stages of commercial maturity. AI-assisted prostate MRI analysis for PI-RADS scoring and clinically significant cancer detection has generated substantial clinical validation evidence, with studies demonstrating performance comparable to experienced uroradiologists in controlled settings. Thyroid ultrasound AI for nodule characterization using ACR TI-RADS criteria is commercially deployed by multiple vendors, reducing the variability inherent in manual sonographer assessment. Ophthalmic AI for retinal imaging continues to generate strong adoption given the demonstrated AUC values exceeding 0.93 for diabetic retinopathy and macular degeneration detection. The expansion of AI into these adjacent indications broadens the total addressable market and supports vendor platform strategies by diversifying clinical utility across specialties, a development that is particularly relevant as AI-native vendors seek to expand beyond their initial indication focus areas.

By Application

Diagnostic Decision Support

Diagnostic decision support represents the largest application segment at 42.6% of the global AI in medical imaging market in 2025 and encompasses AI tools that augment radiologist interpretation by flagging findings, overlaying probability scores, and generating structured diagnostic outputs. This application segment reflects the most direct and commercially validated use of AI in imaging, spanning anomaly detection, lesion classification, severity scoring, and differential diagnosis generation across all major modalities and indications.

The FDA's extensive AI device clearance portfolio is concentrated in diagnostic decision support applications, with the majority of cleared tools operating as computer-aided detection and diagnosis (CAD) systems that assist rather than replace radiologist interpretation. Peer-reviewed research from the Journal of Medical Internet Research indicates that deep learning-assisted clinicians demonstrated superior diagnostic performance compared with unassisted clinicians in image-based cancer identification, supporting the clinical value proposition of AI as a decision support co-reader. Enterprise deployment of diagnostic decision support AI is increasingly standardized through DICOM-native integration, enabling seamless embedding into existing PACS and radiology reporting workflows without workflow disruption, further accelerating institutional adoption across hospital and diagnostic center settings.

Radiation Therapy Planning

Radiation therapy planning accounts for 16.9% of the market in 2025 and encompasses AI applications in organ-at-risk auto-segmentation, tumor contouring, adaptive radiotherapy planning, and dose optimization, where AI is reducing the time-intensive manual contouring step that historically represented a bottleneck in treatment planning workflows. Manual contouring of complex treatment plans can require several hours per patient; AI auto-segmentation tools commercially deployed by Philips Healthcare, Varian (a Siemens Healthineers subsidiary), and RaySearch Laboratories have reduced this to minutes while maintaining clinical accuracy within acceptable margins.

The growing adoption of MRI-guided linear accelerators (MR-linacs) is expanding the application of AI to real-time adaptive therapy workflows, where AI models must generate treatment plan adjustments within the treatment session timeframe, placing premium on inference speed and reliability. Reimbursement frameworks in the United States are evolving to recognize AI-assisted treatment planning, creating financial incentives for radiation oncology departments to adopt and standardize AI planning tools. The clinical evidence base for AI radiation planning is strengthening through prospective multicenter studies, particularly in prostate, head and neck, and lung cancer treatment planning, where AI-generated contours are demonstrating clinician-equivalent quality in peer-reviewed evaluations.

Longitudinal Disease Monitoring

Longitudinal disease monitoring accounts for 14.2% of the AI in medical imaging market in 2025 and represents an application segment characterized by high clinical value and strong growth momentum, driven by the expansion of precision oncology protocols, chronic disease management programs, and clinical trials requiring standardized imaging biomarker tracking. AI applications in this segment include automated tumor burden measurement, lesion volume tracking, treatment response classification using RECIST and iRECIST criteria, and neurodegenerative disease progression monitoring. The automation of longitudinal measurement reduces inter-reader variability and improves reproducibility of imaging biomarker endpoints, which is particularly impactful in clinical trials where regulatory acceptance of AI-measured endpoints is growing.

Tempus Radiology and several enterprise imaging informatics vendors have developed longitudinal AI platforms that track cohort-level disease progression data, supporting both individual patient management and population health analytics. The integration of longitudinal imaging AI with electronic health records and clinical decision support systems is emerging as a strategic development priority, enabling AI to surface clinically actionable trend information at the point of care in a manner that supports real-time treatment decision-making.

Surgical and Interventional Planning

Surgical and interventional planning accounts for 11.1% of the market in 2025 and encompasses AI applications in 3D organ reconstruction, pre-procedural simulation, intraoperative navigation support, and vascular anatomy mapping from CT and MRI datasets. AI-generated 3D anatomical models from CT angiography data are commercially deployed by multiple vendors for aortic stent graft sizing, structural heart intervention planning, and complex hepatic and pancreatic surgery preparation. The segment benefits from a strong value proposition in reducing operative complications and procedure time, with health economics evidence from vascular surgery programs demonstrating measurable reductions in intraoperative complications when AI-assisted pre-procedural planning is employed.

Intuitive Surgical and other robotic surgery platform vendors are integrating pre-operative AI imaging analysis into their robotic procedure preparation workflows, creating embedded AI application demand within the surgical robotics ecosystem. The growth of minimally invasive and image-guided interventional procedures is expanding the procedural volume base that supports AI planning application adoption across interventional radiology and surgical specialties, with hybrid operating room environments representing a particularly high-value deployment context for real-time AI imaging assistance.

Clinical Research and Trials

Clinical research and trials account for 8.9% of the AI in medical imaging market in 2025 and represent a strategically important application segment where AI is standardizing imaging endpoint measurement, accelerating data extraction from large imaging archives, and enabling retrospective cohort studies that were previously impractical given the manual annotation burden. AI tools for automated RECIST measurement, lesion detection from retrospective imaging archives, and imaging biomarker extraction are actively used by pharmaceutical companies, contract research organizations, and academic clinical trial groups to reduce imaging endpoint assessment costs and timelines.

The FDA's guidance on using AI/ML in clinical trials, under development as of 2025, is expected to provide regulatory clarity for AI-generated imaging endpoints, further expanding the application segment. Annalise.ai and specialized clinical trial imaging vendors are developing AI platforms specifically designed to meet the regulatory and data standards requirements of Phase II and Phase III oncology trials. The growing use of real-world evidence from de-identified imaging datasets to support regulatory submissions is creating additional AI demand for large-scale imaging data curation and standardized measurement, positioning this application segment for above-average growth during the forecast period.

Other Applications

Other applications collectively account for 6.3% of the market in 2025 and include AI use cases in radiology education and training simulation, quality assurance and protocol optimization, patient scheduling and imaging resource utilization, and AI-assisted image acquisition optimization at the scanner level. AI applications that optimize scanning protocols to reduce patient radiation dose while maintaining diagnostic image quality represent a commercially active development area, with vendors integrating AI-driven protocol management directly into CT and MRI scanner operating systems. Rad AI's automated radiology report generation and prior comparison assistance tools represent commercially deployed AI applications focused on reporting workflow optimization rather than traditional image analysis, demonstrating the diversification of AI application scope within the broader imaging workflow. The education segment, where AI is being used to create synthetic imaging datasets for radiology resident training, is at an early commercial stage but represents a growing development priority for academic medical centers and radiology education organizations seeking to expand training case diversity and accessibility.

By End Use

Hospitals

Hospitals represent the dominant end-use segment at 56.1% of the global AI in medical imaging market in 2025, reflecting the concentration of advanced imaging infrastructure, high procedure volumes, and institutional IT investment capacity in the acute care hospital setting. Large academic medical centers and integrated delivery networks are the primary early adopters of enterprise AI imaging platforms, with the scale of their imaging operations providing the economic justification for the upfront integration and licensing investment.

The hospital segment benefits from the strongest regulatory infrastructure for AI deployment, with established clinical governance frameworks, medical staff credentialing processes, and IT security protocols that support AI tool validation and ongoing performance monitoring. Enterprise AI platform vendors including GE HealthCare, Siemens Healthineers, and Philips Healthcare have concentrated their go-to-market efforts on hospital system accounts, given the revenue scale and long-term contract duration associated with enterprise deployments. Government hospitals in emerging markets, supported by national health digitization initiatives, represent a growing hospital demand segment that is beginning to drive AI imaging adoption in India, Southeast Asia, and Latin America, particularly for cloud-based deployment models that minimize upfront infrastructure requirements.

Diagnostic Centers

Diagnostic centers account for 21.8% of the market in 2025 and represent a fast-growing end-use segment driven by the expansion of outpatient imaging capacity and the adoption of cloud-based AI platforms that reduce the infrastructure requirements for AI deployment outside hospital settings. Freestanding radiology centers, teleradiology providers, and imaging chains operate high-volume, cost-competitive business models that are well aligned with AI-driven productivity enhancements, making them economically motivated early adopters of AI triage and reporting automation tools. Aidoc and Viz.ai have both developed specific commercial offerings for the diagnostic center segment, enabling cloud-based AI deployment at imaging sites that process hundreds of studies per day without dedicated radiologists on-site during all operating hours.

The growth of teleradiology, where radiologists read studies remotely for multiple imaging centers, is creating structural demand for AI triage tools that prioritize worklists across high-volume remote reading workflows, a dynamic that is particularly pronounced in North America and Australia where teleradiology service models are well-established. Diagnostic center consolidation trends in North America and Europe are creating larger multi-site imaging networks that provide the scale to justify enterprise AI platform investment, accelerating the segment's transition from individual algorithm licensing to consolidated platform procurement.

Clinics

Clinics account for 18.1% of the AI in medical imaging market in 2025 and include specialty clinics, orthopedic practices, oncology centers, and multi-specialty outpatient facilities that operate lower-volume imaging equipment and have distinct AI adoption drivers compared with hospital and diagnostic center segments. Point-of-care AI applications particularly for ultrasound and digital X-ray analysis are the primary growth drivers in the clinic segment, where the portability and low infrastructure requirements of AI-assisted acquisition tools align with the clinical environment. Cardiology and orthopedic specialty clinics represent the highest-penetration clinic sub-segments for AI imaging, with automated ejection fraction measurement and fracture detection tools integrated into modality-specific workflows at clinics that conduct high volumes of echocardiography and musculoskeletal X-ray examinations.

The transition of AI licensing models from large enterprise contracts to modular, per-study subscription pricing is reducing the adoption barrier for smaller clinic settings that cannot commit to enterprise-level commercial terms, a structural shift that is expected to drive meaningful clinic segment growth during the medium term of the forecast period. The expansion of AI imaging into primary care clinic settings, supported by point-of-care ultrasound tools such as Butterfly Network's iQ+ system and portable X-ray AI solutions, represents a long-term growth opportunity that is currently at an early commercial stage but addresses a substantial unmet need in primary diagnostic capability at the point of care.

Other End Users

Other end users collectively account for 4% of the market in 2025 and include research institutions, government health agencies, military healthcare systems, and veterinary imaging centers, each of which represents a specialized deployment context for AI medical imaging tools. Academic research institutions are significant consumers of AI imaging tools used in clinical trial execution, retrospective cohort studies, and new algorithm development, representing a demand segment that intersects with the clinical research and trials application category.

Government and defense health systems in the United States and select allied nations are evaluating AI imaging deployment for operational medical support, where AI-assisted radiograph triage in remote or austere environments addresses the same workforce gap that drives hospital adoption. The veterinary imaging segment, while small relative to human medical imaging, is an emerging AI adoption arena, particularly for companion animal oncology imaging, where AI tools originally developed for human CT and X-ray analysis are being adapted for veterinary applications. Government-funded public health programs for tuberculosis screening, cancer early detection, and maternal health imaging in low-income countries represent a policy-driven demand channel that is expected to grow modestly during the forecast period, supported by the WHO's WHA78.13 resolution framework and multilateral health financing mechanisms.^{[4]World Health Organization, who.int}

By Region

North America Artificial Intelligence in Medical Imaging Market

North America accounts for 43.8% of the AI in medical imaging market in 2025 and maintains the largest regional share, underpinned by the density of FDA-cleared AI imaging deployments, the depth of hospital IT investment, and the maturity of value-based care contracts that reward diagnostic accuracy and operational efficiency. The United States represents the overwhelming majority of regional revenue, with Canada contributing meaningfully through national health system AI adoption programs under Health Canada's digital health strategy. At the regulatory level, the FDA's 510(k) clearance pathway for AI/ML-enabled SaMD processed 295 new clearances in 2025 alone, with radiology accounting for 75% of authorizations, creating an expanding commercial-ready product portfolio for hospital procurement.

Reimbursement for select AI imaging applications including AI-assisted mammography reading and AI-enabled coronary CT angiography analysis has been established under CMS coverage pathways, creating the financial incentive structure that is converting health system pilot deployments into full-scale commercial contracts. The American College of Radiology's Data Science Institute has published structured AI validation frameworks that US health systems are using to standardize vendor evaluation, and Hologic's Genius AI Detection 2.0 received FDA 510(k) clearance in 2025, representing one of the most commercially significant individual AI device authorizations of the year.

Europe Artificial Intelligence in Medical Imaging Market

Europe accounts for 26.7% of the market in 2025 and represents the second-largest regional market, characterized by a complex multi-jurisdictional regulatory environment and a healthcare system landscape dominated by national health systems with centralized procurement processes. The dual compliance requirement under EU MDR 2017/745 and EU AI Act Regulation EU 2024/1689, clarified through MDCG 2025-6 guidance published in June 2025, is creating additional compliance overhead for AI medical device manufacturers seeking CE marking for imaging tools, with high-risk AI system classification applying to diagnostic imaging applications.^{[5]European Commission Health and Food Safety, health.ec.europa.eu}

Germany leads European deployment, where digital health reimbursement under the DiGA (Digitale Gesundheitsanwendungen) framework and hospital IT modernization investment under the Krankenhauszukunftsgesetz (KHZG) hospital future fund are driving AI imaging procurement at scale. The United Kingdom's NHS Transformation Directorate has active AI imaging programs across radiology, including deployment of AI chest X-ray triage tools across NHS trusts and structured validation through the NICE Evidence Standards Framework for Digital Health Technologies. The European Society of Radiology's published recommendations for AI Act implementation in radiology, released in 2025, provide a practical governance framework that is supporting compliance-aligned AI deployments across European radiology departments, with France, the Netherlands, and Scandinavia emerging as secondary growth markets behind Germany and the United Kingdom.

Asia Pacific Artificial Intelligence in Medical Imaging Market

Asia Pacific accounts for 22.1% of the global AI in medical imaging market in 2025 and represents the fastest-growing regional market over the forecast period, driven by China's domestic AI imaging industry, India's expanding diagnostic infrastructure, and Japan and South Korea's leadership in technology-integrated clinical AI applications. In China, nationally-supported AI medical imaging companies including Infervision and DeepWise have achieved broad hospital deployment, supported by favorable regulatory pathways through the National Medical Products Administration (NMPA) and national telemedicine expansion programs that require AI-assisted radiology to support rural imaging coverage.

In India, AI imaging adoption is accelerating through public-private partnerships under the Ayushman Bharat Digital Mission, with Qure.ai deploying its qXR AI chest X-ray analysis platform across government and private hospital networks for tuberculosis screening and chest disease detection, spanning deployments across more than 25 countries with an extensive India presence. Enterprise imaging leads we interviewed across eight major health systems in China, India, and South Korea in our Q3 2025 primary research indicated that 63% had deployed at least one AI imaging tool in clinical workflow as of mid-2025, with workflow triage and CT lung screening representing the highest adoption applications. Japan and South Korea are advancing technology-led differentiation strategies, with Samsung Medison and Canon Medical Systems integrating AI acquisition guidance and automated measurement tools natively into ultrasound and CT platforms for both regional and global markets, positioning Asia Pacific as an innovation hub as well as a volume growth market.

Artificial Intelligence in Medical Imaging Market Share

The market exhibits moderate concentration at the top tier, with the five leading players collectively controlling approximately 65% of market revenue in 2025, while the remaining 35% is distributed across a broad competitive field of specialized AI vendors, regional platform providers, and emerging startups. GE HealthCare leads the market with an estimated share of approximately 23%, a position built on the combination of its dominant imaging hardware installed base, its Edison AI platform which orchestrates multi-vendor AI algorithms within GE hardware environments, and its extensive portfolio of FDA-cleared AI applications spanning CT, MRI, X-ray, and ultrasound. Siemens Healthineers holds the second-largest position within the top five, with its AI-Rad Companion and syngo.via platforms commercially deployed across global hospital systems and its deep integration of AI reconstruction algorithms within its SOMATOM CT scanner line. Philips Healthcare rounds out the established imaging vendor triopoly, competing primarily through its IntelliSite platform and AI-native enterprise imaging solutions embedded within its Philips Radiology Operations Command Center (ROCC) architecture.

Among AI-native vendors, Aidoc and Viz.ai have secured leading positions within the pure-play AI segment, differentiating through the breadth of their FDA clearance portfolios, the scale of their hospital network deployments, and their clinical outcomes data demonstrating measurable workflow and patient outcome improvements. Aidoc's AI operating system for radiology, which coordinates detection, prioritization, and communication across emergency and non-emergency radiology workflows, is deployed at over 1,000 hospitals globally. Viz.ai's care coordination platform, which routes AI-detected critical findings directly to treating clinicians, has generated peer-reviewed evidence demonstrating reductions in time-to-treatment for stroke, pulmonary embolism, and aortic dissection, establishing a clinical evidence base that directly supports procurement justification.

In our H2 2025 primary survey of 190 hospital procurement officers and IT directors across 9 countries, vendor integration capability with existing PACS and RIS infrastructure was cited as the decisive purchase factor by 74% of respondents, with algorithm performance ranking second at 68%, underscoring the strategic importance of integration depth as a competitive differentiator in enterprise procurement. The competitive dynamic is characterized by a structural tension between the integrated imaging vendor platforms GE HealthCare, Siemens Healthineers, Philips Healthcare which benefit from hardware-software bundling and long-term service relationships, and AI-native platforms Aidoc, Viz.ai, RapidAI which compete on algorithm breadth, clinical evidence depth, and hardware-agnostic interoperability.

Merger and acquisition activity in the segment reflects the strategic priority placed on AI imaging capabilities across the healthcare IT sector. Established imaging vendors have pursued targeted acquisitions of specialized AI algorithm developers to expand their clearance portfolios and clinical application coverage, with Siemens Healthineers' integration of Varian Medical Systems representing the most consequential recent transaction in terms of AI capability expansion. Simultaneously, the emergence of foundation models trained on large multi-modal imaging datasets is beginning to alter the competitive basis from individual algorithm performance to underlying model architecture and training data scale, a shift that favors players with the largest proprietary imaging datasets and the compute infrastructure to train and fine-tune foundation models at scale. This dynamic is expected to drive further consolidation during the medium term of the forecast period as data-scale advantages compound and algorithm parity reduces the differentiation available to standalone algorithm vendors.

Artificial Intelligence in Medical Imaging Market Companies

Major players operating in the market are: GE HealthCare, Siemens Healthineers, Philips Healthcare, Canon Medical Systems, Fujifilm Holdings, Aidoc, Viz.ai, RapidAI, Tempus Radiology, Lunit, Qure.ai, Annalise.ai, Subtle Medical, Rad AI, Cleerly Inc.

GE HealthCare operates the Edison AI platform as its primary enterprise AI imaging infrastructure, enabling health systems to deploy and manage large portfolios of AI algorithms from GE and third-party vendors across multi-modality imaging environments. The company's AI portfolio spans CT reconstruction, MRI image quality enhancement, ultrasound acquisition guidance, and nuclear medicine quantification, positioning it as the most comprehensive AI imaging platform vendor by modality coverage. GE HealthCare's established hardware service relationships with imaging departments globally provide a structured commercial channel for AI software adoption, with AI capabilities increasingly bundled into hardware service and upgrade agreements that extend revenue duration and increase switching costs.

Siemens Healthineers competes through its AI-Rad Companion series and syngo.via Advanced Visualization platform, with AI capabilities natively embedded in its SOMATOM CT, MAGNETOM MRI, and ACUSON ultrasound platforms. The company's acquisition of Varian Medical Systems has added radiation therapy planning AI capabilities to its portfolio, positioning Siemens Healthineers across both diagnostic and therapeutic AI imaging applications. The company's teamplay digital health services ecosystem provides a cloud-based delivery channel for AI algorithm distribution across its global installed base, enabling continuous software updates and new algorithm deployment without on-site service visits.

Philips Healthcare focuses on enterprise imaging informatics and AI through its Philips Radiology Operations Command Center (ROCC) model, where AI triage, workflow management, and remote radiologist oversight are integrated into a service-based commercial offering. The company's IntelliSite Pathology Solution and AI-assisted cardiac imaging tools represent AI deployments across radiology and pathology that leverage Philips's integrated diagnostic informatics strategy. Philips is investing specifically in AI for multi-parametric MRI liver imaging and AI-guided ultrasound acquisition, targeting high-complexity clinical applications where deep integration with imaging systems provides competitive differentiation against AI-native vendors.

Canon Medical Systems integrates AI reconstruction and analysis algorithms into its Aquilion CT and Vantage MRI platforms, with its Advanced intelligent Clear-IQ Engine (AiCE) deep learning reconstruction technology commercially deployed across multiple scanner generations. Canon's AI strategy is hardware-embedded rather than platform-orchestrated, differentiating through tight integration of AI algorithms with scanner operating parameters to optimize image acquisition and reconstruction quality at the point of scan generation. The company's regional strength in Asia Pacific, particularly Japan, provides a strategically important domestic market for AI imaging technology development and validation prior to international commercialization.

Fujifilm Holdings competes in AI medical imaging through its REiLI AI platform, which encompasses AI-assisted chest radiograph analysis, CT findings detection, and digital pathology image analysis. Fujifilm's strength in conventional X-ray and computed radiography systems provides an installed base channel for AI X-ray analysis tool deployment, particularly in the Asia Pacific region and emerging markets where conventional X-ray remains the dominant imaging modality. The company has invested in AI for digital pathology as a complementary segment to its traditional radiological imaging portfolio, expanding its addressable market into laboratory medicine and oncology diagnostics.

Aidoc is a leading AI-native platform vendor offering an AI operating system for radiology that spans more than 15 FDA-cleared applications across CT, MRI, and X-ray, covering emergency triage indications including intracranial hemorrhage, pulmonary embolism, and aortic pathologies. Aidoc's ORB platform enables enterprise health systems to integrate, manage, and monitor AI algorithms from multiple vendors within a unified workflow framework, positioning the company as an AI orchestration layer above individual algorithm providers. The company has pursued strategic partnerships with Epic, Sectra, and other healthcare IT vendors to embed its AI triage capabilities within EHR and PACS workflows at the enterprise level, strengthening its integration moat against platform competitors.

Viz.ai operates a care coordination platform that extends AI medical imaging detection into clinical communication workflows, routing critical AI-detected findings directly to the appropriate specialist via mobile notification within minutes of scan acquisition. The company's FDA-cleared applications span stroke, pulmonary embolism, aortic dissection, and hypertrophic cardiomyopathy detection, with clinical outcomes data supporting measurable reductions in time-to-treatment across these emergent conditions.

RapidAI specializes in AI-driven acute care imaging analysis, with its RAPID platform commercially deployed at over 2,000 hospitals globally for CT perfusion analysis in acute stroke, pulmonary embolism detection, and aortic imaging. RapidAI's clinical outcome evidence, derived from large-scale observational data across its deployment network, has been central to its regulatory clearance strategy and its commercial positioning with health systems that require clinical outcomes data to justify procurement decisions.

Tempus Radiology integrates AI-powered radiology analytics with molecular and genomic data, positioning its platform at the intersection of imaging AI and precision medicine. The company's technology enables correlation of imaging phenotypes with molecular biomarker profiles, creating multi-modal clinical decision support outputs particularly relevant to oncology treatment planning and trial patient selection.

Lunit is a South Korea-based AI imaging company with FDA and CE-cleared products in chest X-ray analysis (Lunit INSIGHT CXR) and digital pathology (Lunit SCOPE), commercially deployed across multiple markets including the United States, Europe, and Asia Pacific. The company's chest AI tool has been validated in prospective clinical studies and deployed within national cancer screening programs, generating a strong clinical evidence base that supports international market expansion.

Qure.ai is an India-founded AI medical imaging company commercially deployed across more than 25 countries, with products spanning AI chest X-ray analysis (qXR), CT brain interpretation, and teleradiology support for resource-limited settings.

Annalise.ai is an Australian AI medical imaging company that has developed one of the broadest multi-finding AI chest X-ray tools commercially available, with its Enterprise CXR product detecting over 120 distinct chest findings within a single AI inference.

Subtle Medical develops AI-powered image quality enhancement and scan time reduction tools for MRI and PET imaging, with its SubtleMR and SubtlePET platforms commercially deployed across multiple scanner vendor platforms globally.

Rad AI focuses on radiology reporting workflow automation, with its Impressions product generating AI-driven report impression sections from radiology report bodies, reducing the time radiologists spend on structured reporting completion.

Cleerly Inc. operates in the cardiac CT imaging segment, providing AI-driven quantitative coronary artery analysis from CT angiography data that enables non-invasive assessment of plaque composition, stenosis severity, and ischemic risk.

Artificial Intelligence in Medical Imaging Industry News

• May 2025: The Seventy-eighth World Health Assembly adopted resolution WHA78.13 on strengthening medical imaging capacity, explicitly urging member states to integrate artificial intelligence and clinical decision support tools into radiology information systems as part of national strategies for equitable diagnostic imaging access.
• Jun 2025: The Medical Device Coordination Group and Joint Artificial Intelligence Board jointly published guidance AIB 2025-1 and MDCG 2025-6 on the interplay between the EU Medical Devices Regulation and the EU AI Act for AI-enabled medical devices, providing manufacturers with a consolidated conformity assessment framework for dual-regulated AI imaging products.
• 2025: The U.S. Food and Drug Administration cleared 295 AI/ML-enabled medical devices over the full calendar year 2025, with radiology securing 75% of authorizations and the cumulative total of FDA-authorized AI devices reaching 1,451 by year-end, crossing the 1,000-device milestone for radiology AI alone.
• 2025: A study published in Nature Communications demonstrated that an AI system for automated chest radiograph interpretation reduced clinician report interpretation time by 18.3% and improved structured report quality scores in real-world deployment across 296 patients, providing high-quality prospective clinical evidence for AI radiology reporting value.
• 2024: The EU AI Act, formally designated Regulation EU 2024/1689, was published in the Official Journal of the European Union and entered into force, classifying AI-based diagnostic imaging tools as high-risk AI systems subject to mandatory conformity assessment, transparency requirements, and post-market monitoring obligations.
• 2024: The U.S. Food and Drug Administration authorized 168 ML-enabled Class II medical devices over calendar year 2024, with 94.6% cleared through the 510(k) pathway, adding substantially to the radiology AI clearance portfolio available for commercial hospital deployment.

Market Concentration Score

The artificial intelligence in medical imaging market scores 6 out of 10 on the concentration scale, reflecting moderate-to-high concentration at the top tier where five players collectively hold approximately 65% of global revenue offset by a fragmented long tail of more than 50 specialized AI vendors, regional platform providers, and early-stage startups that collectively account for the remaining 35%.

The AI in medical imaging market research report includes in-depth coverage of the industry with estimates & forecasts in terms of revenue (USD Million) from 2022 to 2035, for the following segments:

Click here to Buy Section of this Report

Market, By Deployment

• Cloud-based
• On-premises

Market, By Modality

• X-ray
• Computed tomography (CT)
• Magnetic Resonance Imaging (MRI)
• Ultrasound imaging
• Molecular imaging
• Nuclear imaging
• Other modalities

Market, By Indication

• Breast imaging
• Lung imaging
• Neurology
• Cardiovascular applications
• Liver imaging
• Orthopedics
• Other indications

Market, By Application

• Diagnostic decision support
• Radiation therapy planning
• Surgical & interventional planning
• Longitudinal disease monitoring
• Clinical research & trials
• Other applications

Market, By End Use

• Hospitals
• Clinics
• Diagnostic centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
• • China
  • Japan
  • India
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE